Tear Production After Bilateral Main Lacrimal Gland Resection in Rabbits

Bhattacharya, Dhruva; Yuan, Ning; Zhao, Fangkun; Stevenson, William; Chen, Rongji; Zhang, Jinsong; Wang, Mingwu

doi:10.1167/iovs.15-17550

Cited by 35 publications

(65 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous attempts to establish DED through incomplete dacryoadenectomy in rabbits have not removed the superior OLG. 15,17,18,30,31,39 After numerous dissections of necropsy samples, we found it impossible to remove what we describe as the superior OLG through the periorbital incisions described in these reports. As we have, however, recently demonstrated, the SLG makes an important contribution to tear production.…”

Section: Discussionmentioning

confidence: 86%

“…48,51,53,54 Changes in aquaporin expression and/or function may underlie some of the residual tear production. 15 Harder's gland is an unlikely source as it produces a small amount of a predominantly lipid-based emulsion. 35,55 Because our simple and safe surgical method completely ablates all of the orbital LG tissues, our model provides an excellent means to study the in vivo compensatory mechanisms of the conjunctival and corneal tissues in a setting of aqueous deficient DED.…”

Section: Discussionmentioning

confidence: 99%

“…To remove the ILG, a curvilinear incision is made through the skin and the subcutaneous tissues surrounding the posterior and inferior orbit similar to (but more extensive than in) previously described methods. 15,17,31,37 The posterior (lateral) canthus tendon is also exposed, facilitating the identification and removal of the posterior portion of the ILG, which lies partially under this structure in some animals. Care must be used in this region, as a branch of the external carotid is in close proximity to or in direct contact with, the terminal portion of the ILG.…”

Section: Removal Of the Lgsmentioning

confidence: 99%

“…The size of the globe, the well-defined eyelid anatomy, the level of expression of drug-inactivating carboxylesterases, and the LG histology of rabbits are much closer to those of the human than the eyes of rats and mice. 8,[14][15][16] At least 12 novel rabbit models of DED have been reported. The majority of them attempt to reduce tear production by either removing LGs or impeding their function.…”

Section: Introductionmentioning

confidence: 99%

“…Partially impaired LGs may still produce significant tear volumes with at times compensatory tear overproduction by residual LGs. 22 Surgical models that involve partial resection of the orbital LG tissues, 15,17,18,30,31 as well as surgical denervation of the LG, are limited by significant residual tear production. 24 The origin of the residual tears in these models remains uncertain; possible sources include the unresected LGs, the accessory lacrimal glands, and residual orbital LG tissues, each alone or in combination.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy

Honkanen¹,

Huang

Huang³

et al. 2019

Current Eye Research

View full text Add to dashboard Cite

Purpose/Aim: Dry eye disease (DED), common and suboptimally treated, is in need of novel animal models to understand its pathophysiology and assess the efficacy and other parameters of new pharmacological agents for its treatment. The more than 10 rabbit models of DED described to date have significant limitations including induction of mild disease, lack of consistency, and off-target effects when chemical agents are used for disease induction. Our aim was to develop a new model of chronic DED in rabbits that overcomes the limitations of existing models. Materials and Methods: We performed a complete surgical resection of all orbital lacrimal glands (LGs; dacryoadenectomy) in normal adult New Zealand White rabbits. One week after removal of the nictitating membrane, we surgically removed the orbital superior LG, followed by removal of the palpebral superior LG, and finally removal of the inferior LG. Surgery was performed under anesthesia, required about 1 h/eye, and was well-tolerated. Results: Dacryoadenectomy induced severe DED, evidenced by >90% reduction in the tear break up time test, 50% reduction in the Schirmer tear test, 10% increase in tear osmolarity, and a marked increase in the rose bengal staining score. DED was sustained and essentially unchanged for the eight weeks of observation. Sham-operated rabbits showed no such changes, with the exception of a nonsignificant and transient reduction in the tear break up time test, a response to ocular surgery. Conclusions: This model of stable, chronic, predominantly aqueous-deficient DED recapitulates key clinical and histological features of human DED and is suitable for the study of ocular surface homeostasis, of the pathophysiology of DED, and of the efficacy of candidate drugs for DED treatment.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Removal Of the Lgsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy

Honkanen¹,

Huang

Huang³

et al. 2019

Current Eye Research

View full text Add to dashboard Cite

show abstract

Topical administration of ambroxol eye drops augments tear secretion in rabbits

Bhattacharya

Wang³

et al. 2021

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Protective effects of carbenoxolone, an 11β-HSD1 inhibitor, against chemical induced dry eye syndrome

et al. 2017

View full text Add to dashboard Cite

Dry eye syndrome (DES) is a disorder of the eye due to tear deficiency or excessive evaporation that causes damage to the eye and is associated with discomfort and dryness. 11β-Hydroxysteroid dehydrogenase 1 (11β-HSD1) is an enzyme that converts inactive cortisone to active cortisol. Recently, 11β-HSD1 has been expressed in human and rodent eyes and has been recognized as a target of glaucoma. In this study, the therapeutic effects and underlying mechanisms of topical carbenoxolone, an 11β-HSD1 inhibitor, were investigated in benzalkonium chloride (BAC)-treated human conjunctival epithelial cells and a rat DES model. In the in vitro study, carbenoxolone dose-dependently inhibited cell death and 11β-HSD1 activity in BAC-treated human conjunctival epithelial cells. For the in vivo study, carbenoxolone or a solvent was administered to the BAC-induced DES model twice daily. BAC-treated rat eyes showed significant increases in ocular surface damage, a reduction of tears, decrease corneal thickness, corneal basement membrane destruction, apoptosis in the conjunctival epithelium, and expression of pro-inflammatory cytokines (TNF-α and IL-6) and 11β-HSD1. These effects of BAC were reversed by topical carbenoxolone treatment. These results demonstrate that carbenoxolone can prevent DES by inhibiting pro-inflammatory cytokine expression and cell death of the corneal and conjunctival epithelium via inhibition of both 11β-HSD1 activity and expression in the eyes of BAC-treated rats. It is suggested that topical 11β-HSD1 inhibitors may provide a new therapeutic window in the prevention and/or treatment of DES.

show abstract

Tear Production After Bilateral Main Lacrimal Gland Resection in Rabbits

Abstract: In the absence of NM, HG, and main LG in rabbits, tear secretion was not decreased and significant improvement of dry eye phenotypes observed with time AE. Conjunctival AQPs are possibly involved in a compensatory tear fluid production.

Cited by 35 publications

References 59 publications

A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy

A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy

Topical administration of ambroxol eye drops augments tear secretion in rabbits

Protective effects of carbenoxolone, an 11β-HSD1 inhibitor, against chemical induced dry eye syndrome

Contact Info

Product

Resources

About